2021 Fiscal Year Final Research Report
Mechanism of action of VEGF in immune suppression: Difference between normal and tumor immunity
Project/Area Number |
20K16553
|
Research Category |
Grant-in-Aid for Early-Career Scientists
|
Allocation Type | Multi-year Fund |
Review Section |
Basic Section 52010:General internal medicine-related
|
Research Institution | Kagoshima University |
Principal Investigator |
|
Project Period (FY) |
2020-04-01 – 2022-03-31
|
Keywords | 血管内皮増殖因子 / 2次リンパ節 / 3次リンパ節 / VEGF121 / VEGF165 |
Outline of Final Research Achievements |
In this study, we used mice overexpressing vascular endothelial growth factor (VEGF) in a B cell-specific manner and compared the histopathology within secondary lymph nodes of B cell-specific VEGF-expressing mice and wild-type mice in four groups after treatment with ovalbumin. The results showed that CD11b+Gr1+Myeloid-derived suppressor cells (MDSCs) within the lymph nodes tended to increase, but no significant differences were observed. We also observed proliferation of regulatory T cells, which were inferred to play a part in tumor evasion. We developed an ELISA system capable of measuring VEGF121,165 subtypes and found that VEGF in the blood was predominantly 121 rather than 165.
|
Free Research Field |
臨床検査医学
|
Academic Significance and Societal Importance of the Research Achievements |
VEGF が外来抗原に対して免疫抑制効果を示す機序を ovalbumin 皮下投与後のリンパ節を観察することにより探索した。VEGF の過剰が 制御性T細胞の増殖を示すことは、腫瘍の免疫逃避機構の解明の一端として VEGF が関与している可能性を示唆する内容であった。また、血中 VEGF の主たるサブタイプが 165 よりも 121 であることを発見したことは、癌治療における抗 VEGF 戦略において重要な発見だったと考える。
|